Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 Inhibitors

Role of serum thymidine kinase-1 (TK1) activity in patients (pts) with hormone receptor positive (HR+) advanced breast cancer (ABC) treated with endocrine therapy (ET) in the EFECT trial.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.12031 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 12031-12031 ◽

Cited By ~ 1

Author(s):

Luca Malorni ◽

Chiara Biagioni ◽

Amelia McCartney ◽

Gaia Schiavon ◽

Mattias Bergqvist ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Thymidine Kinase ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Advanced Breast ◽

Thymidine Kinase 1 ◽

Serum Thymidine Kinase 1

Novel Strategies in Hormone Receptor-Positive Advanced Breast Cancer: Overcoming Endocrine Resistance

Current Breast Cancer Reports ◽

10.1007/s12609-016-0228-1 ◽

2016 ◽

Vol 8 (4) ◽

pp. 193-205 ◽

Cited By ~ 2

Author(s):

A. C. Garrido-Castro ◽

O. Metzger-Filho

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Endocrine Resistance ◽

Advanced Breast ◽

The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer

Current Treatment Options in Oncology ◽

10.1007/s11864-017-0443-7 ◽

2017 ◽

Vol 18 (1) ◽

Cited By ~ 22

Author(s):

Ami N. Shah ◽

Massimo Cristofanilli

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Advanced Breast ◽

Ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative advanced breast cancer (ABC) who received no prior therapy for advanced disease

Geburtshilfe und Frauenheilkunde ◽

10.1055/s-0036-1592812 ◽

2016 ◽

Vol 76 (10) ◽

Author(s):

EM Grischke ◽

A Nusch ◽

N Marschner ◽

W Abenhardt ◽

J Wilke ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Advanced Disease ◽

Advanced Breast ◽

Prior Therapy ◽

PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer

Contemporary Clinical Trials Communications ◽

10.1016/j.conctc.2018.05.012 ◽

2018 ◽

Vol 10 ◽

pp. 190-192

Author(s):

Filipa Lynce ◽

Mervat Saleh ◽

Ayesha Shajahan-Haq ◽

Christopher Gallagher ◽

Asma Dilawari ◽

...

Keyword(s):

Breast Cancer ◽

African American ◽

Advanced Breast Cancer ◽

African American Women ◽

Phase Ii ◽

Hormone Receptor ◽

Advanced Breast ◽

Safety Study ◽

American Women ◽

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

Annals of Oncology ◽

10.1093/annonc/mdu009 ◽

2014 ◽

Vol 25 (4) ◽

pp. 808-815 ◽

Cited By ~ 87

Author(s):

H.S. Rugo ◽

K.I. Pritchard ◽

M. Gnant ◽

S. Noguchi ◽

M. Piccart ◽

...

Keyword(s):

Breast Cancer ◽

Adverse Events ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Time Course ◽

Advanced Breast ◽

Adverse Event Management of mTOR Inhibitors During Treatment of Hormone Receptor–Positive Advanced Breast Cancer: Considerations for Oncologists

Clinical Breast Cancer ◽

10.1016/j.clbc.2014.03.002 ◽

2014 ◽

Vol 14 (5) ◽

pp. 297-308 ◽

Cited By ~ 20

Author(s):

Denise A. Yardley

Keyword(s):

Breast Cancer ◽

Adverse Event ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Mtor Inhibitors ◽

Advanced Breast ◽

Event Management ◽

Adverse Event Management

Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer

The Breast ◽

10.1016/j.breast.2014.09.006 ◽

2014 ◽

Vol 23 (6) ◽

pp. 710-720 ◽

Cited By ~ 24

Author(s):

Elsa Dalmau ◽

Alejandra Armengol-Alonso ◽

Montserrat Muñoz ◽

Miguel Ángel Seguí-Palmer

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Therapy ◽

Hormone Receptor ◽

Advanced Breast ◽

Current Status ◽

The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial

Journal of Bone Oncology ◽

10.1016/j.jbo.2018.09.010 ◽

2019 ◽

Vol 14 ◽

pp. 100199 ◽

Cited By ~ 1

Author(s):

Peyman Hadji ◽

Oliver Stoetzer ◽

Thomas Decker ◽

Christian M. Kurbacher ◽

Frederik Marmé ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Bone Health ◽

Hormone Receptor ◽

Mammalian Target Of Rapamycin ◽

Advanced Breast ◽

Phase Iiib ◽

The Impact

Phase III trial of chidamide, a subtype-selective histone deacetylase (HDAC) inhibitor, in combination with exemestane in patients with hormone receptor-positive advanced breast cancer

Annals of Oncology ◽

10.1093/annonc/mdy424.011 ◽

2018 ◽

Vol 29 ◽

pp. viii709 ◽

Cited By ~ 1

Author(s):

Z. Jiang ◽

W. Li ◽

X. Hu ◽

Q. Zhang ◽

T. Sun ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Histone Deacetylase ◽

Hdac Inhibitor ◽

Hormone Receptor ◽

Advanced Breast ◽

Phase Iii ◽

Phase Iii Trial ◽

Subtype Selective